Differential Uptake of Nanoparticles by Human M1 and M2 Polarized Macrophages: Protein Corona as a Critical Determinant

Binnemars-Postma, Karin; Hoopen, Hetty W. M. Ten; Storm, Gert; Prakash, Jai

doi:10.2217/nnm-2016-0233

Cited by 73 publications

(62 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies already evaluated the effect of macrophage polarization on nanoparticle uptake, but they obtained contrasting results, depending on the conditions used during the studies and, most importantly, on the type on nanoparticle used. [64][65][66] Ideally, for intravenous injectable nanosystems and the "hitchhike" effect to the infarcted heart by recruited macrophages to take place, the aim is to obtain a nanosystem that is able to associate with the macrophages' surface, without being taken-up. To understand which type of macrophage was presenting a higher nanoparticle-cell association rate versus uptake, we evaluated the interactions between the hitchhiking nanoparticles and the differentiated M1-and M2-like macrophages derived from both human and murine precursors.…”

Section: Cell-nanoparticle Interactions With Primary Macrophagesmentioning

confidence: 99%

Dual-peptide functionalized acetalated dextran-based nanoparticles for sequential targeting of macrophages during myocardial infarction

et al. 2020

View full text Add to dashboard Cite

The advent of nanomedicine has recently started to innovate the treatment of cardiovascular diseases, in particular myocardial infarction. Although current approaches are very promising, there is still an urgent need for advanced targeting strategies. In this work, the exploitation of macrophage recruitment is proposed as a novel and synergistic approach to improve the addressability of the infarcted myocardium achieved by current peptide-based heart targeting strategies. For this purpose, an acetalated dextran-based nanosystem is designed and successfully functionalized with two different peptides, atrial natriuretic peptide (ANP) and linTT1, which target, respectively, cardiac cells and macrophages associated with atherosclerotic plaques. The biocompatibility of the nanocarrier is screened on both macrophage cell lines and primary macrophages, showing high safety, in particular after functionalization of the nanoparticles' surface. Furthermore, the system shows higher association versus uptake ratio towards M2-like macrophages (approximately 2-fold and 6-fold increase in murine and human primary M2-like macrophages, respectively, compared to M1-like). Overall, the results demonstrate that the nanosystem has potential to exploit the "hitchhike" effect on M2-like macrophages and potentially improve, in a dual targeting strategy, the ability of the ANP peptide to target infarcted heart. † Electronic supplementary information (ESI) available. See

show abstract

Section: Cell-nanoparticle Interactions With Primary Macrophagesmentioning

confidence: 99%

Dual-peptide functionalized acetalated dextran-based nanoparticles for sequential targeting of macrophages during myocardial infarction

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Furthermore, nanoparticle internalization decreased inflammatory cytokine secretion. These trends were corroborated by Binnemars‐Postma et al, who investigated the effect of protein coronas on silica nanoparticle uptake by M1 or M2 macrophages …”

Section: Synthetic Biomaterials To Target Tams In Cancer By Systemic mentioning

confidence: 99%

Progress on Modulating Tumor‐Associated Macrophages with Biomaterials

2019

View full text Add to dashboard Cite

Tumor‐associated macrophages (TAMs) are a complex and heterogeneous population of cells within the tumor microenvironment. In many tumor types, TAMs contribute toward tumor malignancy and are therefore a therapeutic target of interest. Here, three major strategies for regulating TAMs are highlighted, emphasizing the role of biomaterials in these approaches. First, systemic methods for targeting tumor‐associated macrophage are summarized and limitations to both passive and active targeting approaches considered. Second, lessons learned from the significant literature on wound healing and macrophage response to implanted biomaterials are discussed with the vision of applying these principles to localized, biomaterial‐based modulation of tumor‐associated macrophage. Finally, the developing field of engineered macrophages, including genetic engineering and integration with biomaterials or drug delivery systems, is examined. Analysis of major challenges in the field along with exciting opportunities for the future of macrophage‐based therapies in oncology are included.

show abstract

“…Consequently, various anticancer therapeutics have been linked or modified with HA to increase their cellular uptake and therefore their pharmacokinetic effect on cancer cells. 122,123 For example, Figueroa et al showed how pro-apoptotic protein-HA bioconjugates can reduce at least 3-fold the cell viability of CD44 overexpressing cancer cells versus normal cells. 124 The ONCOFID™-S bioconjugate, which links the anticancer drug irinotecan and HA, showed a significant increment in drug efficacy in vitro and improved mice survival in ovarian cancer.…”

Section: Lectinsmentioning

confidence: 99%

<p>Smart Targeting To Improve Cancer Therapeutics</p>

Morales‐Cruz¹,

Delgado²,

Castillo³

et al. 2019

DDDT

102

101

View full text Add to dashboard Cite

Cancer is the second largest cause of death worldwide with the number of new cancer cases predicted to grow significantly in the next decades. Biotechnology and medicine can and should work hand-in-hand to improve cancer diagnosis and treatment efficacy. However, success has been frequently limited, in particular when treating late-stage solid tumors. There still is the need to develop smart and synergistic therapeutic approaches to achieve the synthesis of strong and effective drugs and delivery systems. Much interest has been paid to the development of smart drug delivery systems (drug-loaded particles) that utilize passive targeting, active targeting, and/or stimulus responsiveness strategies. This review will summarize some main ideas about the effect of each strategy and how the combination of some or all of them has shown to be effective. After a brief introduction of current cancer therapies and their limitations, we describe the biological barriers that nanoparticles need to overcome, followed by presenting different types of drug delivery systems to improve drug accumulation in tumors. Then, we describe cancer cell membrane targets that increase cellular drug uptake through active targeting mechanisms. Stimulusresponsive targeting is also discussed by looking at the intra-and extracellular conditions for specific drug release. We include a significant amount of information summarized in tables and figures on nanoparticle-based therapeutics, PEGylated drugs, different ligands for the design of active-targeted systems, and targeting of different organs. We also discuss some still prevailing fundamental limitations of these approaches, eg, by occlusion of targeting ligands.

show abstract

Differential Uptake of Nanoparticles by Human M1 and M2 Polarized Macrophages: Protein Corona as a Critical Determinant

Abstract: The observed differential uptake by M1 and M2 macrophages will help understand the fate of nanoparticles in vivo.

Cited by 73 publications

References 49 publications

Dual-peptide functionalized acetalated dextran-based nanoparticles for sequential targeting of macrophages during myocardial infarction

Dual-peptide functionalized acetalated dextran-based nanoparticles for sequential targeting of macrophages during myocardial infarction

Progress on Modulating Tumor‐Associated Macrophages with Biomaterials

<p>Smart Targeting To Improve Cancer Therapeutics</p>

Contact Info

Product

Resources

About